Cardiology Respiratory
REVEAL 2.0 Risk Score for Pulmonary Arterial Hypertension
Predicts 1-year survival in pulmonary arterial hypertension (PAH) using clinical, haemodynamic, and echocardiographic parameters.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Selexipag · Pulmonary Arterial Hypertension
- Macitentan · Pulmonary Arterial Hypertension
- Sildenafil · PDE5 Inhibitor — Pulmonary Arterial Hypertension
- Bosentan · Endothelin Receptor Antagonist — Pulmonary Arterial Hypertension
- Ambrisentan · Pulmonary Arterial Hypertension
- Macitentan · Pulmonary Arterial Hypertension
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.